bimagrumab plus semaglutide Concentration–time profile of bimagrumab in healthy older adults and

The “muscle tax” might finally have a solution. GLP-1s changed obesity treatment. But losing muscle was always the tradeoff. New Phase 2 data on bimagrumab + semaglutide shows we might not have

29.68

★★★★☆4.8 (126)

Bimagrumab: The Weight Loss Drug That Builds Muscle Instead of Burning It

20.54

★★★★★4.9 (98)

Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism

25.49

★★★★★5.0 (157)

Combination GLP-1 Therapy Shows Fat Mass Loss While Preserving Lean Mass in Adults with Obesity

24.25

★★★★★4.7 (84)

Factbox-Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

25.52

★★★★★4.9 (203)

Combined use of semaglutide with an investigational monoclonal antibody called bimagrumab produced significant fat mass loss while preserving lean mass, results from the phase 2b BELIEVE study found. http://ms.spr.ly/6180SLSUq

28.22

★★★★★5.0 (176)

New phase 2 data just published in Nature Medicine on bimagrumab combined with semaglutide. Swipe for the breakdown. Follow @adam_nessim for more. Source: Heymsfield et al., Nature Medicine, March 2, 2026

25.33

★★★★★4.8 (132)